ArticleSignal transduction and targeted therapy2023
Diffuse midline glioma treated with epigenetic agent-based immunotherapy.
Article in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epigenetic reprogramming and antitumor immune responses in gliomas: a systematic review.Medical oncology (Northwood, London, England) · 2025Pooled it
- Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma.Molecular therapy. Oncology · 2026Article
- Pilot report of an anti-PD-1/VEGF bispecific antibody for treating recurrent H3K27M-mutant diffuse midline gliomas.Cancer immunology, immunotherapy : CII · 2026Article
- Histone deacetylases: Function in tumor development and therapeutic prospects (Review).Oncology letters · 2026Review
- Aneurysmal formation of periventricular anastomosis is associated with collateral development of Moyamoya disease and its rupture portends poor prognosis: detailed analysis by multivariate statistical and machine learning approaches.Neurosurgical review · 2024Article
- Usefulness of magnetic resonance imaging characteristics in discriminating H3 K27M-mutant gliomas from wildtype gliomas in spinal cord.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Article
- Long-Term Outcomes and Survival Rates of Patients Undergoing Biopsy Vs. Maximum Safe Resection for Thalamic Lesions: A Short Review on Current Evidence.Galen medical journal · 2024Review
- Long-term survival after cordectomy in a case of spinal cord diffuse midline glioma, H3K27-altered: illustrative case.Journal of neurosurgery. Case lessons · 2023Article
- Review
- Advances in Molecular Pathology, Diagnosis and Treatment of Spinal Cord Astrocytomas.Technology in cancer research & treatmentReview
- Combination of oncolytic viruses and immune checkpoint inhibitors for treatment of high-grade gliomas.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.